mRNA-3210 / Moderna - LARVOL DELTA

A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: ModernaTX, Inc. | N=54 ➔ 0 | Active, not recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Metabolic Disorders • Phenylketonuria • Rare Diseases

A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria (clinicaltrials.gov) - P1/2 | N=54 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Metabolic Disorders • Phenylketonuria • Rare Diseases

Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria. (PubMed, Nat Commun) - "These preclinical data were then used to develop translational PK/PD models, which were scaled allometrically to humans to predict starting doses for first-in-human clinical studies for each disease. The predicted first-in-human doses for mRNA-3927, mRNA-3705, and mRNA-3210 were determined to be 0.3, 0.1, and 0.4 mg/kg, respectively."

Journal • Genetic Disorders • Metabolic Disorders • Ophthalmology • Phenylketonuria • Rare Diseases

A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria (clinicaltrials.gov) - P1/2 | N=54 | Recruiting | Sponsor: ModernaTX, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metabolic Disorders • Phenylketonuria • Rare Diseases